Impact of 1.0 mg/Day Dienogest Treatment on Bone Metabolism Markers in Young Women with Dysmenorrhea
article
OA: gold
CC0
⤵ 4 in-corpus citations
AI-generated summary
Treatment of young women with dysmenorrhea using 1.0 mg/day dienogest for 3 months did not significantly alter bone turnover markers TRACP-5b and BAP.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
A low dose of dienogest (DNG) 1 mg/day is useful for treating dysmenorrhea in young women. However, the effect of DNG on bone turnover during bone growth and formation, rather than at maturity, is currently unknown even at low doses. We investigated change in bone turnover after 3 months of DNG 1 mg/day. This retrospective cohort study included young women aged 10–24 years with dysmenorrhea and irregular menstruation. Gonadotropins and the bone metabolism markers TRACP-5b and BAP were compared before and at 3 months after administration of DNG 1 mg/day. There were no significant changes in TRACP-5b (before, 455.6 ± 323.6 mU/dL; 3 months after, 462.1 ± 346.1 mU/dL), BAP (before, 24.7 ± 19.0 μg/L; 3 months after, 25.2 ± 22.3 μg/L), or the TRACP-5b/BAP ratio (before, 22.1 ± 7.0; 3 months after, 21.5 ± 6.3). Administration of DNG 1 mg/day had no significant effect on bone turnover after 3 months during the bone-growth phase in young women.
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (32)
- ACOG Committee Opinion No. 760: Dysmenorrhea and Endometriosis in the Adolescent via openalex
- Chronic pelvic pain and endometriosis: translational evidence of the relationship and implications via openalex
- Endometriosis: A Disease That Remains Enigmatic via openalex
- Endometriosis and the outcome of in vitro fertilization via openalex
- Evaluation of the efficacy, safety, and clinically recommended dose of dienogest in the treatment of primary dysmenorrhea: a randomized, double-blind, multicenter, placebo-controlled study via openalex
- Incidence, symptoms, and signs of endometriosis in fertile and infertile women. via openalex
- Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills via openalex
- W2079128836 via openalex
- W2097096130 via openalex
- W2101417341 via openalex
- W2116358477 via openalex
- W2151598027 via openalex
- W2154381405 via openalex
- W2168850271 via openalex
- W2774725324 via openalex
- W2967986241 via openalex
- W2969319976 via openalex
- W3012860481 via openalex
- W3015863623 via openalex
- W3016126001 via openalex
- W3046109160 via openalex
- W6628434118 via openalex
- W6649758892 via openalex
- W6674469315 via openalex
- W1444169419 via openalex
- W6751471464 via openalex
- W1977691394 via openalex
- W1996855651 via openalex
- W2017229559 via openalex
- W2019372750 via openalex
- W2024901165 via openalex
- W2058262707 via openalex
Cited by (5)
- Endometriosis in adolescents: A literature review 2026
- Comparative Study of 0.5 mg Dienogest Tablets (1 mg/Day) and Continuous Low-Dose Estrogen/Progestin for Dysmenorrhea: A Retrospective Analysis—Influence of Bleeding-Related Factors Such as Endometrial Polyps, Uterine Fibroids, and Adenomyosis 2025
- Efficacy of 0.5 mg Dienogest Tablets in Treating Premenstrual Syndrome-like Symptoms: A Comparative Study with a Low-Dose Estrogen–Progestin Combination 2024
- Dienogest in conjunction with GnRH-a for postoperative management of endometriosis 2024
- Special Issue “Impact of Endometriosis on Women’s Health” 2022
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK